Cellnovo, Home Diagnostics Inc form strategic alliance
LONDON Cellnovo, a London-based medical device company, and Home Diagnostics, a leader in diabetes products, on Thursday announced a strategic alliance that involves integrating technologies and developing distribution opportunities for Cellnovo’s insulin-patch pumps.
The partnership allows both companies to accelerate their growth and has the potential to transform the pump industry, the companies stated in a joint press release. The first phase of the agreement calls for the inclusion of Home Diagnostics TRUE blood glucose technology in the Cellnovo wireless mobile handset. The companies will also begin exploring ways to leverage Home Diagnostics’ distribution network to expand Cellnovo’s presence in the United States and other countries.
“We are extremely excited about our partnership with Home Diagnostics,” said Bill McKeon, Cellnovo CEO. “On a technical level, it will provide our customers with the most advanced blood-glucose monitoring technology available today within our mobile handset. From a business perspective, it provides an extensive distribution network that includes 45,000 points of distribution, leading insurance companies and major product order suppliers.”
The Home Diagnostics blood glucose unit will operate as a built-in meter within the Cellnovo handset, enabling patients to monitor their blood sugar using touchscreen controls and TRUEresult and TRUEtest Test Strips. Like all information in the handset, the glucose readings will be automatically stored and sent wirelessly to physicians, clinicians and family members.
“Our agreement with Cellnovo allows us to leverage the emerging opportunities in the insulin pump market through the most innovative pump system in the industry,” said Joseph Capper, HDI president. “We look forward to helping Cellnovo bring the convenience, ease-of-use and wireless capabilities of their visionary product to diabetes patients throughout the U.S. and beyond.”
The Cellnovo pump, which is available in three models, is a small patch pump that features a wireless, touchscreen operation. With the integration of the Home Diagnostics blood glucose meter, patients can monitor their glucose levels using the same handset that records their insulin use, daily meals and activity levels, making diabetes management easier and more accurate.
“The combination of Home Diagnostics’ leadership technology and its significant distribution channels positions us to not only drive new advancements in health care, but to also bring greater freedom and convenience to diabetes patients worldwide,” McKeon said.
McNeil Consumer Healthcare temporarily suspends operations in Pa. facility
FORT WASHINGTON, Pa. In a statement released Tuesday, McNeil Consumer Healthcare stated: “The quality issues that [the Food and Drug Administration] has observed, many of which we had recently identified in our own quality reviews and communicated to the FDA, are unacceptable to us, and not indicative of how McNeil Consumer Healthcare intends to operate.”
McNeil Consumer Healthcare last week voluntarily recalled all lots that have not yet expired of certain over-the-counter children’s and infants’ liquid products in consultation with the Food and Drug Administration. The agency suggested that McNeil’s Fort Washington, Pa. plant may not be compliant with Good Manufacturing Practices.
“Some of the products included in the recall may contain a higher concentration of active ingredient than is specified; others may contain inactive ingredients that may not meet internal testing requirements; and others may contain tiny particles,” the FDA stated on its Web site.
Both the FDA and McNeil suggested the risk for adverse events associated with the recalled products was relatively low.
Following the recall, McNeil has temporarily suspended production at its Fort Washington production facility. “We will not restart operations until we have taken the necessary corrective actions and can assure the quality of products made there,” McNeil stated. “We will continue to work in close consultation with the FDA to take corrective action and ensure that our quality operations meet the high standards that consumers expect from us.”
Bausch & Lomb gives consumers more ways to ‘soothe’ eyes
MADISON, N.J. Bausch & Lomb on Tuesday announced the U.S. launch of Soothe Xtra Hydration lubricant eye drops. Building on the success of the Soothe XP Xtra Protection formula, new Soothe Xtra Hydration provides a comprehensive over-the-counter portfolio for patients with dry eyes, the company stated.
The Soothe portfolio now is aligned with the most recent international Dry Eye Workshop sponsored by the Tear Film & Ocular Surface Society. DEWS created a new definition of dry eye and helped develop two major classifications of dry eye — aqueous-deficient dry eye and evaporative dry eye.
New Soothe Xtra Hydration, for aqueous-deficient dry-eye therapy, moisturizes and restores the deficient aqueous and mucin layers of the tear film to provide lasting hydration and comfort. It will be available at major retailers in May.
Soothe XP Xtra Protection, for evaporative dry-eye therapy, re-establishes the lipid layer of the tear film to provide up to eight hours of relief. The product is widely available at major retailers.